966 related articles for article (PubMed ID: 19319953)
1. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities.
den Elzen WP; Vossen AC; Cools HJ; Westendorp RG; Kroes AC; Gussekloo J
Vaccine; 2011 Jun; 29(29-30):4869-74. PubMed ID: 21497631
[TBL] [Abstract][Full Text] [Related]
4. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
8. Antibody responses after dose-sparing intradermal influenza vaccination.
Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
[TBL] [Abstract][Full Text] [Related]
10. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
[TBL] [Abstract][Full Text] [Related]
12. Response to a monovalent 2009 influenza A (H1N1) vaccine.
Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
14. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
15. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
[TBL] [Abstract][Full Text] [Related]
16. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
[TBL] [Abstract][Full Text] [Related]
17. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
[TBL] [Abstract][Full Text] [Related]
18. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
20. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]